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Abstract: 
When mesenchymal stem cells (MSC) are used for therapy of 
immunological pathologies, MSCs get into an inflammatory environment 
altering the effectiveness of the treatment. To establish the impact of 
environmental inflammatory factors on MSC’s immunofunction in the mirror 
of intrinsic heterogeneity of mouse MSC population, individual MSC clones 
were generated and characterized. Adipogenic but not osteogenic 
differentiation and pro-angiogenic activity of five independent MSC cell 
lines were similar. Regarding osteogenic differentiation, clones MSC3 and 
MSC6 exhibited poorer capacity than MSC2, MSC4 and MSC5. To study the 
immunosuppressive heterogeneity, in vitro and in vivo experiments have 
been carried out using T-cell proliferation assay and delayed-type 
hypersensitivity (DTH) response, respectively. Remarkable difference was 
found between the clones in their ability to inhibit T-cell proliferation in the 
following order: MSC2≥MSC5>MSC4>MSC3>>MSC6. Nevertheless, the 
differences between the immunosuppressive activities of the individual 
clones disappeared upon pre-treatment of the cells with pro-inflammatory 
cytokines, a procedure called licensing. Stimulation of all clones with IFN-γ 
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and TNF-α resulted in elevation of their inhibitory capability to similar level. 
Nitric oxide (NO) and prostaglandin E2 (PGE2) were identified as major 
mediators of immunofunction of the MSC clones. The above findings were 
also supported by in vivo results. Without licensing, MSC2 inhibited, while 
MSC6 did not affect DTH response. In contrast, pre-stimulation of MSC6 
with inflammatory cytokines resulted in strong suppression by this clone as 
well. Here we have showed that MSC population is functionally 
heterogeneous in term of immunosuppressive function, however, this 
variability is largely reduced under pro-inflammatory conditions.  
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Abstract 
When mesenchymal stem cells (MSC) are used for therapy of immunological pathologies, 
MSCs get into an inflammatory environment altering the effectiveness of the treatment. To 
establish the impact of environmental inflammatory factors on MSC’s immunofunction in the 
mirror of intrinsic heterogeneity of mouse MSC population, individual MSC clones were 
generated and characterized. Adipogenic but not osteogenic differentiation and pro-angiogenic 
activity of five independent MSC cell lines were similar. Regarding osteogenic differentiation, 
clones MSC3 and MSC6 exhibited poorer capacity than MSC2, MSC4 and MSC5. To study the 
immunosuppressive heterogeneity, in vitro and in vivo experiments have been carried out using 
T-cell proliferation assay and delayed-type hypersensitivity (DTH) response, respectively. 
Remarkable difference was found between the clones in their ability to inhibit T-cell proliferation 
in the following order: MSC2≥MSC5>MSC4>MSC3>>MSC6. Nevertheless, the differences 
between the immunosuppressive activities of the individual clones disappeared upon pre-
treatment of the cells with pro-inflammatory cytokines, a procedure called licensing. Stimulation 
of all clones with IFN-γ and TNF-α resulted in elevation of their inhibit ry capability to similar 
level. Nitric oxide (NO) and prostaglandin E2 (PGE2) were identified as major mediators of 
immunofunction of the MSC clones. The above findings were also supported by in vivo results. 
Without licensing, MSC2 inhibited, while MSC6 did not affect DTH response. In contrast, pre-
stimulation of MSC6 with inflammatory cytokines resulted in strong suppression by this clone as 
well. Here we have showed that MSC population is functionally heterogeneous in term of 
immunosuppressive function, however, this variability is largely reduced under pro-inflammatory 
conditions.  
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Introduction 
Mesenchymal stem or stromal cells are adult multipotent fibroblast-like progenitor cells 
present in the bone marrow and virtually in all other organs [1]. The major criteria to define 
MSCs are the plastic adherence in standard culturing conditions, in vitro differentiation capacity 
toward mesodermal lineages i.e., osteoblasts, chondroblasts and adipocytes and the expression of 
specific set of immunophenotypic markers [2]. Moreover, a powerful immunosuppressive 
activity also characterizes MSCs, particularly those isolated from the bone marrow or adipose 
tissue [3]. Due to the ability of differentiation into various tissues and immunomodulatory 
function MSCs have been suggested as a potential tool in regenerative and immunosuppressive 
medicine. Therefore, the safety and efficacy of using MSCs for the treatment of various 
pathological conditions have recently been a matter of intensive investigation [4,5]. Therapy of 
severe refractory acute graft-versus-host disease (GVHD) [6] has already received conditional 
approval in several countries. Moreover, treatment of myocardial infarction is one of the most 
successful clinical improvements being at phase II clinical trial [7,8]. Benefits of MSC therapy 
originate from that the MSCs promote tissue regeneration via differentiation and engraftment into 
the injured recipient tissue and/or production of wide panel of bioactive molecules supporting 
angiogenesis, stimulating endogenous stem cell recruitment and differentiation, modulating 
immune response by diminishing inflammation [9]. Although growing body of data has been 
accumulated suggesting clonal heterogeneity of MSCs, it is still not well established, how the 
heterogeneity of MSC population affects the therapeutical application. 
The heterogeneity of MSCs has been demonstrated regarding morphology, cell surface 
marker expression, differentiation potential and transcriptome [10-12]. It was first proposed by 
Friedenstein and his colleagues who described variable osteogenic potential of bone marrow-
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derived fibroblastoid colonies in vivo [13]. This study was followed by more than a dozen studies 
showing that MSC clones displayed various capacity of multilineage differentiation in vitro and 
in vivo (reviewed in [10]). On the other hand, immunosuppressive functions of single cell-derived 
MSC populations have been improperly compared. The few studies available resulted in 
controversial data showing either similar or different immunomodulatory capacities of single 
cell-derived MSC lines [14-16]. Recent findings have provided evidence that the 
immunosuppressive function of these cells is modulated by an inflammatory microenvironment 
[15,17]. Whether licensing by pro-inflammatory cytokines affects the immunosuppressive 
function at clonal level has not yet been revealed. 
The current work aims to explore the heterogeneity of mouse bone marrow derived MSC 
population with a special focus on the consequence of the heterogeneity to the immune function. 
Differentiation properties and pro-angiogenic activities are characterized at clonal level. Our 
results show that the analyzed 5 MSC clones are similar in immunophenotype, adipogenic 
differentiation and pro-angiogenic activity. Two clones, MSC3 and MSC6 show poorer capacity 
to differentiate toward osteogenic direction. Most importantly, remarkable differences are 
observed in immunosuppressive capabilities between the individual clones both in vitro and in 
vivo. However, the variability in the immune function disappears when MSCs are licensed by 
inflammatory cytokines indicating that the functions of individual cells are largely dependent on 
their surrounding environment. 
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Materials and Methods 
Cell culture 
Mesenchymal stem cells were isolated from bone marrow of one C57BL/6 mouse and 
characterized as described previously [18,19]. The cells were cultured in DMEM (Gibco®) 
supplemented with 10% fetal bovine serum (FBS) (Gibco®), penicillin-streptomycin (Sigma-
Aldrich) and 2 mM L-glutamine (Gibco®) (complete medium, CM) in a humidified incubator 
with 5% CO2 at 37°C. 
MSC culture at passage 10 was cloned with limiting dilution in DMEM/F-12 (Gibco®) 
supplemented with 10% FBS and 5% horse serum (Gibco®) by plating 1 cell/well in a 96-well 
culture plate (Orange Scientific). Five monoclonal MSC cultures labeled as MSC2-6 were 
randomly selected under a CKX41 inverted light microscope (Olympus Holding Europa GmbH) 
and further cultured up to 5-10 passages.  
 
Flow cytometry 
Cells (5 × 105 cells/sample) were labeled for 30 min at 4°C with various antibodies: anti-
mouse Sca-1 labeled with phycoerythrin (PE), CD44-PE, biotin-conjugated CD119 (BD 
Pharmingen) followed by streptavidin-PE (Sigma-Aldrich). Mouse Mesenchymal Stem Cell 
Marker Antibody Panel (BD Pharmingen) was used to analyze CD11b, CD45, CD29 and CD106 
according to manufacturer’s instructions. The proper isotype matched immunoglobulins were 
used as controls. Cell analysis was performed by FACSCalibur flow cytometer (Becton 
Dickinson). Evaluation of the data was carried out with CellQuestTM software (Becton 
Dickinson). 
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Detection of adipogenic and osteogenic differentiation 
Adipogenic medium consisted of DMEM/F-12 supplemented with 10% FBS, penicillin-
streptomycin, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX; Sigma-Aldrich), 10 µM 
dexamethasone (Sigma-Aldrich), 66 µM indomethacin (Sigma-Aldrich), 2 µL/mL insulin (insulin 
lispro injection, 100 U/mL, Humalog®) [20]. MSCs were maintained in adipogenic medium for 3 
days, detached with 0.05 % trypsin-EDTA, fixed with 4% paraformaldehyde (Sigma-Aldrich) 
and lipid droplets were stained with fluorescent AdipoRed™ according to the manufacturer’s 
instructions (Lonza). Fluorescent lipid droplets were detected with Axioskop 2 Mot fluorescence 
microscope (Carl Zeiss) using EC Plan-Neofluar 20x/0.5 objective (Carl Zeiss). For quantitation 
of lipid accumulation in adipocytes, the cells (5 × 105 cells/sample) were labeled with 
AdipoRed™ as described above and quantified by FACSCalibur flow cytometer using 
CellQuestTM software. 
Osteogenic medium was composed of CM and 10 mM β-glycerophosphate (Sigma-
Aldrich), 50 µg/mL L-ascorbic acid 2-phosphate (Sigma-Aldrich) and 0.1 µM hydrocortisone 
(Sigma-Aldrich). MSCs were cultured in osteogenic medium for 14 days then fixed with 8% 
formaldehyde and stained with Alizarin Red S (Sigma-Aldrich) solution (pH 4.1) to detect 
calcium deposition. Photomicrographs were taken with Olympus CKX41 inverted light 
microscope and Olympus Camedia C-5060 camera (Olympus Holding Europa GmbH).  
 
In vitro pre-vascular structure assay 
Co-culture of MSCs and mouse heart endothelioma cells, H5V (kindly provided by Vizler 
C of HAS, BRC, Hungary) [21] was initiated in a ratio of 1 : 1 in a 24-well plate at a cell density 
of 2 × 104 cells/well. Pre-vascular structure formation was evaluated as follows: 5 randomly 
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selected non-overlapping areas of co-plated cells were examined by Olympus Cell-R 
fluorescence microscope (Olympus Holding Europa GmbH) using UPlanSApo 4x/0.16 objective. 
The lengths of pre-vascular structures were quantified by measuring with CellR Imaging 
Software (Olympus Holding Europa GmbH) after 3 days of cell culture. 
 
T-cell proliferation assay 
First, MSCs were seeded on a 96-well plate at cell density of 5 × 103 cells/100 µL CM in a 
well. Mesenteric, inguinal and brachial lymph nodes from Balb/C mice were dissected. Lymph 
nodes were disrupted mechanically to release most of the leukocytes. Leukocytes were harvested 
by centrifugation and resuspended in phosphate buffered saline (PBS) containing 5% FBS at a 
final concentration of 2 × 106 cells/mL. Carboxyfluorescein diacetate succinimidyl ester (CFSE, 
CellTrace™ CFSE Cell Proliferation Kit, Life Technologies) was added to leukocytes at a final 
concentration of 2.5 µM and cells were incubated in dark for 5 minutes at room temperature. 
Leukocytes were washed twice with fresh RPMI culture medium (Gibco®) then 2 × 105 cells 
were added to the pre-seeded MSCs in 100 µL of RPMI containing 10% FBS, 50µM β-
mercaptoethanol (Sigma-Aldrich) and 5 µg/mL Concanavalin A (ConA, Sigma-Aldrich). In 
blocking experiments, nitric oxide synthase (NOS2), prostaglandin-endoperoxide synthase 2 
(cyclooxygenase 2) (PTGS2) or indolamine-2,3-dioxygenase (IDO) inhibitors, 1 mM NG-methyl-
L-arginine acetate salt, L-NMMA (Sigma-Aldrich), 10 µM, indomethacin (Sigma-Aldrich) or 
1 mM 1-methyl-L-tryptophan (Sigma-Aldrich), respectively were added to MSC/leukocyte co-
cultures. After 72 h of incubation, non-adherent leukocytes were collected, washed with PBS, 
settled by centrifugation and resuspended in PBS supplemented with 1% FBS, 0.1% sodium-
azide (FACS-buffer) and 10 µg/mL propidium-iodide. Cell proliferation was measured by flow 
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cytometry. Evaluation of the data was carried out using CellQuestTM software (Becton 
Dickinson) and ModFit LTTM Version 2.0. software (Verity Software House, Inc). T-cell 
proliferation was evaluated as proliferating fraction (PF) calculated as follows: PF % = number of 
proliferating T-cells / total number of T-cells × 100. 
In some experiments, MSCs were pre-treated with a mixture of 100 ng/mL mouse 
recombinant IFN-γ (R&D Systems) and 50 ng/mL TNF-α (kindly provided by Duda E of HAS, 
BRC Hungary) [22] for 24 h then washed twice with CM and T-cell proliferation was tested as 
described above.  
 
Western blot analysis 
Mesenchymal stromal cells were lysed (107 MSCs/mL) in RIPA buffer containing 10 mM 
Tris•HCl and 150 mM NaCl (Molar Chemicals), 1% Triton X (Sigma-Aldrich), 0.5% sodium 
deoxycholate (Reanal), 0.1% SDS (Sigma-Aldrich), 2 mM EDTA (Reanal) and 1 mM PMSF 
(Sigma-Aldrich). The lysates were analyzed by Western blotting after running the samples on a 
10% SDS-polyacrylamide gel then electroblotted onto a nitrocellulose membrane (Whatman® 
Protran®). After blocking with 3% cold fish gelatin (Sigma-Aldrich) in Tris buffered saline (TBS) 
and 0.05% Tween® 20 (Sigma-Aldrich), the membranes were incubated with rabbit anti-Gal-1 
(produced in our laboratory, [19]) then HRP-conjugated anti-rabbit immunoglobulin (Dako). 
Rabbit anti-β-actin antibody (Abcam) was used as a loading control. Immunoreactive proteins 
were visualized with AmershamTM ECL Prime Western Blotting Detection Reagent (GE 
Healthcare Life Sciences) and analyzed using EC3 Imaging System furnished with a CCD Chemi 
410 Camera (Ultra-Violet Products). As molecular mass standard, Page RulerTM Prestained 
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Protein Ladder (Fermentas) was used. Density of the bands was measured by VisionWorks®LS 
Image Acquisition and Analysis Software (Ultra-Violet Products). 
 
 
Quantitative real-time PCR  
MSCs (105 cells/well) were plated in 35 mm diameter culture dishes in CM. After 24 h, 
fresh CM was added with or without 100 ng/mL IFN-γ and 50 ng/mL TNF-α then further 
incubated for 24 h. Finally, total RNA was extracted using Nucleospin RNA II isolation kit 
(MACHEREY-NAGEL GmbH) according to manufacturer’s instruction. RevertAid H Minus 
First Strand cDNA Synthesis Kit (Thermo Fisher Scientific Inc.) was used to obtain cDNA from 
2 µg of total RNA/reaction. Quantitative PCR (qPCR) was performed using TaqMan® Gene 
Expression Master Mix (Life Technologies) for Ptgs2, Nos2 and Ido1 and AccuPower® 2X 
Greenstar qPCR Master Mix (Bioneer) for angiopoietin-1 (Angpt1), vascular endothelial growth 
factor A (Vegfa), transforming growth factor beta 1 (Tgfb1) and galectin-1 (Lgals1) in 
RotoGene3000 instrument (Corbett Life Science). Relative gene expression normalized to 
glyceraldehyde 3-phosphate dehydrogenase (Gapdh) was presented as 2(CtGapdh-CtGOI). TaqMan® 
Gene Expression Assays were commercially available for Ptgs2 (Mm00478374_m1), Nos2 
(Mm01309902_m1), Ido1 (Mm00492586_m1*) and Gapdh (Mm99999915_g1). Primers for 
qPCR were designed using Universal Probe Library Assay Design program (Roche Applied 
Science) for Gapdh, Angpt1, Lgals1, Tgfb1 and Vegfa. The following primer sequences were 
used: Gapdh fwd: tttgatgttagtggggtctcg, rev: agcttgtcatcaacgggaag; Angpt1 fwd: 
cggatttctcttcccagaaac, rev: tccgacttcatattttccacaa; Lgals1 fwd: ctctcgggtggagtcttctg, rev: 
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ggtttgagattcaggttgctg; Tgfb1 fwd: tggagcaacatgtggaact, rev: cagcagccggttaccaag; Vegfa fwd: 
aaaaacgaaagcgcaagaaa, rev: tttctccgctctgaacaagg. 
 
Induction of Delayed Type Hypersensitivity (DTH) response  
Ovalbumin (1 mg/mL in PBS, Sigma-Aldrich) was emulsified at a 1 : 1 ratio in complete 
Freund’s adjuvant (Sigma-Aldrich). Male C57BL/6 mice (6- to 8-weeks-old) were immunized by 
subcutan injection of 100 µg ovalbumin/animal. Subcutan injection of PBS with complete 
Freund’s adjuvant served as a control. Cells (106 MSCs/animal) or PBS were injected 
intraperitoneally in 200 µL volume. After 4 days, DTH was initiated by challenging with 250 µg 
heat-aggregated ovalbumin in 12.5 µL PBS or PBS alone injected into the right or left hind 
footpad, respectively. After 48 h, ovalbumin-induced footpad thickness was measured using a 
caliper and calculated as follows: (T48 hours - U48 hours) - (T0 hours - U0 hours), where T and U are 
thickness of ovalbumin treated and ovalbumin untreated footpads, respectively. All animal 
studies were approved by the Animal Care and Use Committee of the National Medical Center 
(Budapest, Hungary) in accordance with the national and international law and regulations of 
animal experiments. 
 
 
Statistical analysis 
Statistical analysis was performed using one-way analysis of variance test (ANOVA) in 
GraphPad Prism Version 6.03 (GraphPad Software). When significant (p < 0.05) by ANOVA, 
pairwise comparisons of experimental groups were carried out using Fisher’s least significant 
difference (LSD) method as a post hoc test. For statistical analysis of qPCR data non-parametric 
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Kruskal-Wallis test followed by Mann-Whitney test was used. Differences were considered 
statistically significant with a p value less than 0.05 (set at *p < 0.05, **p < 0.01, ***p < 0.001). 
 
 
Results 
Characterization of monoclonal MSC cell lines  
Each clone expressed uniformly Sca-1, CD29, CD44, CD106 and CD119 (Fig. 1) at similar 
degree and none of the clones expressed lineage specific markers CD11b and CD45 (Fig. 1).  
In vitro osteoblast differentiation was assayed with Alisarin Red S staining showing that MSC2, 
MSC4 and MSC5 exhibited strong, MSC3 and MSC6 weak in vitro osteoblast differentiation 
(Fig. 2A). During adipocyte differentiation, all MSC clones accumulated comparable amount of 
neutral lipids into intracellular lipid droplets (Fig. 2B, C), indicating that these cells had similar 
adipogenic differentiation potential. 
 
In vitro pro-angiogenic activity of MSC clones  
We have previously reported that MSCs and H5V endothelial cells spontaneously 
arranged into vessel-like structures within 3 days of co-culture [19]. Moreover, deficiency in 
galectin-1, a pro-angiogenic lectin in MSCs resulted in reduced formation of pre-vascular 
structures [19]. To determine whether individual MSC clones supported similarly or differently 
the shaping of these structures, in vitro pro-angiogenic assays were performed with the 
monoclonal MSC cultures. While neither MSC clones nor H5V endothelial cells formed pre-
vascular structures alone, co-culturing any of the clones with H5V resulted in arrangement into 
pre-vascular structures (Fig. 3A) in similar extent (Fig. 3B).  
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Analysis of pro-angiogenic factor expression by qPCR showed that all clones expressed similar 
level of Angpt1, Vegfa and Lgals1 mRNAs (Fig. 3C). Results of qPCR experiments (Fig. 3C) 
were validated by Western blot analysis of galectin-1 protein (Supplementary Fig. S1) 
 
MSC clones vary in in vitro immunosuppressive activity  
Immunomodulatory properties of MSC clones were assessed in vitro by analyzing their 
effect on Con A-activated T-cell proliferation. Proliferation of T-cells was robustfully diminished 
in the presence of MSC2, MSC4 and MSC5 while poorly inhibited by MSC3 and MSC6 (Fig. 
4A, B). Differences were significant and the order of their inhibitory capacity was as follows: 
MSC2 ≥ MSC5 > MSC4 > MSC3 >> MSC6 (Fig. 4B).  
Our aim was to determine whether variability between the clones regarding their inhibitory 
activity was reflected in the expression levels of immunomodulatory factors. Therefore, the 
expression levels of mRNAs encoding NOS2, PTGS2 responsible for the production of anti-
inflammatory mediators, NO and PGE2, respectively and IDO1 creating a tryptophan deprived 
environment were analyzed. Relative Nos2 mRNA level well coincided with anti-proliferative 
function of the clones as it was expressed at higher levels in MSC2, MSC5 (significant) and 
MSC4 (not significant) than in MSC3 and was undetectable in MSC6 (Fig. 5A). Expression of 
Ptgs2 did not show any remarkable difference between the clones (Fig. 5B). The two enzymes, 
NOS2 and PTGS2 seemed to be important in the inhibitory function of the most 
immunosuppressive clone MSC2. The inhibition of T-cell proliferation by MSC2 was blocked 
entirely with L-NMMA and partially with indomethacin, inhibitors of NOS2 and PTGS2, 
respectively (Fig. 6, Unstimulated MSC). In contrast, the presence of these inhibitors did not 
affect the activity of the least immunosuppressive clone MSC6 (Fig. 6, Unstimulated MSC). 
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Expression of other immunomodulatory factors such as Tgfb1 (Supplementary Fig. S2) and 
Lgals1 (Fig. 3C) were similar and Ido1 mRNA expression couldn’t be detected in any of the 
clones (Supplementary Fig. S3A).  
To model the in vivo inflammatory environment in which MSCs act as anti-inflammatory 
cells, the monoclonal cell lines were pre-treated with Th1 type cytokines, IFN-γ and TNF-α and 
the effect of the licenced MSC on T-cell proliferation was analyzed. Licensing by pro-
inflammatory cytokines, MSC3 and MSC6 clones, which exerted poor inhibitory activity, 
blocked the T-cell proliferation at similar extent to the clones with strong inhibition. In contrast, 
licensing was not or barely able to further enhance immunosuppressive activity of MSC2, MSC4 
and MSC5 (Fig. 4C). Expression of Nos2 gene largely increased in all clones to an equal level 
upon IFN-γ and TNF-α treatment. Nevertheless, the degree of elevation was the most remarkable 
in clones with poor inhibitory activity (Fig. 5A). On the other hand, Ptgs2 expression was also 
upregulated in all clones, although much less than that of Nos2 gene (Fig. 5B). Furthermore, 
unstimulated MSC clones didn’t express Ido1, unless they were pre-activated with IFN-γ and 
TNF-α. Pro-inflammatory cytokine treatment triggered Ido1 mRNA expression as well 
(Supplementary Fig. S3A). 
To determine the potential role of anti-inflammatory mediators in the inhibition of T-cell 
proliferation under inflammatory conditions, anti-proliferative activities of the clones were 
blocked with inhibitors. Immunosuppressive activity of licenced MSC2 and MSC6 were assayed 
in the presence of L-NMMA and confirmed the crucial role of NO. On the other hand, the 
presence of indomethacin slightly affected MSC6 but not MSC2 activity (Fig. 6, MSC pre-treated 
with IFN-γ + TNF-α) suggesting a less pronounced function of PGE2. In addition, neither MSC2 
nor MSC6 activities were influenced by IDO1 inhibitor 1-MT, independently from IFN-γ and 
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TNF-α-activation (Supplementary Fig. S3B) indicating that IDO1 did not participate in the 
immunosuppression by these clones. 
 
Ovalbumin-induced Delayed Type Hypersensitivity (DTH) model supports in vitro findings 
The effect of the most and least immunosuppressive MSC2 and MSC6 clones, 
respectively, was tested in ovalbumin-induced DTH response in mice. MSC2 significantly 
prevented the thickening of footpad while MSC6 injection resulted in no change compared to the 
control (treatment without MSCs) (Fig. 7). Nevertheless, when pre-treated with IFN-γ and TNF-α 
prior to injection, MSC6 diminished DTH reaction similarly to non-treated MSC2 clone while 
immunosuppressive activity of MSC2 was not affected by licensing (data not shown). 
 
Discussion 
It has been proposed that the heterogeneity of MSCs may be partially responsible for the 
divergent outcomes of MSC-based clinical trials [11]. Several studies reported that various MSC 
clones differed in differentiation potential into mesenchymal lineages [10]. Other functional 
properties, such as pro-angiogenic effect has not yet been extensively investigated at clonal level. 
In addition, the data regarding heterogeneity in immunosuppressive properties of MSC 
population is insufficient and meets discrepancy. While Xu et al. argued that single cell-derived 
MSC populations possessed uniform immunomodulating capacities [14] others demonstrated 
large differences in immunosuppression at clonal level [15,16].  
In the present study, clonal diversity of murine bone marrow MSCs was examined with a special 
focus on the in vitro and in vivo immunosuppression. Moreover, in vitro osteoblast and adipocyte 
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differentiation and pro-angiogenic effect of the MSC clones were also compared as a part of the 
characterization of the clones. 
In according to previous results regarding variable osteogenic differentiation of single cell-
derived human or murine MSCs [15,23-25] we found that the clones exhibited different 
osteoblast potential in vitro. On the other hand, the analyzed clones similarly differentiated 
toward adipocytes. It has recently been described that MSCs produce wide array of factors 
influencing endothelial cell growth and angiogenesis [26] and thereby inducing capillary-like 
structure formation in vitro [27,28]. We previously demonstrated that MSCs spontaneously 
formed interconnected pre-vascular structures on a galectin-1 dependent fashion when co-
cultured with H5V endothelial cells [19]. However, only one paper analyzed angiogenic activity 
of MSCs at clonal level [29]. Burns et al. reported that two telomerase-immortalized human MSC 
(hMSC-TERT20) clones distinctly formed cord-like structures due to their different extracellular 
matrix protein production and the key role of galectin-1 had been proven in in vitro and in vivo 
angiogenesis in serum-deprived condition in spite of equivalent expression of two major pro-
angiogenic factors (VEGFA, ANGPT1) [29]. We analyzed the in vitro pro-angiogenic activity of 
MSC2-6 clones in a pre-vascular structure assay in which MSCs were co-cultured with H5V 
cells. The clones expressed comparable level of pro-angiogenic factors, including Vegfa, Angpt1 
and Lgals1and accordingly, formed similar pre-vascular structures. The controversy between our 
and Burns’s results may derive from the different experimental conditions, mainly that human 
MSCs were genetically modified and cultured under serum depriving condition.  
The major aspect of this work has been the comparison of the immunomodulatory activity 
of MSCs at clonal level. The isolated MSC clones differently influenced the proliferation of Con 
A-activated T-cells ranging from 30% to 70% of inhibition. In this term, MSC2, MSC4 and 
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MSC5 strongly inhibited T-cell proliferation while inhibitory activities of MSC3 and MSC6 were 
significantly weaker. Our results were in accordance with those published by others [15,16] 
reporting difference between the immunosuppressive activities of single cell-derived MSC 
clones. The diversity in the inhibition of T-cell proliferation could be explained by the different 
expression of immunomodulatory gene Nos2, responsible for the generation of a crucial 
mediator, NO. Elevated level of Nos2 expression was found in naïve MSC2, MSC4 and MSC5, 
the clones representing high inhibitory activity. Whereas it was expressed at a lower level or was 
undetectable in MSC3 and MSC6, respectively, the clones slightly inhibiting T-cell proliferation. 
The central role of NO in inhibition of T-cell proliferation was also confirmed using NOS2 
inhibitor, L-NMMA which blocked the inhibitory effect of the most immunosuppressive clone, 
MSC2. These results were in good agreement with previous experimental data [15,16,30]. 
Expression of Ptgs2 playing role in PGE2 synthesis showed no significant difference among the 
clones. Studies examining the function of PGE2 in immunosuppression by murine MSCs 
produced controversial data namely PGE2 had either important [31] minor [30] or no role [14-
16]. Yet, the importance of PGE2 was unambiguously shown here by using an inhibitor of 
PTGS2, indomethacin. Interestingly, blocking NOS2 resulted in full inhibition of T-cell anti-
proliferative effect of MSC2, the most immunosuppressive clone while indomethacin only 
incompletely reversed T-cell growth. Our recent result [32] might serve an explanation for this 
phenomenon; PGE2 secretion by MSC seems to be promoted by a NO-dependent signaling 
pathway, since L-NMMA inhibits not only NO production but also partially diminishes PGE2 
secretion, resulting in complete recovery of T-cell proliferation. 
Recently, a growing body of data supports the idea that the biological functions of MSCs 
are strongly influenced by the surrounding microenvironment, especially the inflamed milieu. 
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Activation, termed as licensing [33] is triggered by pro-inflammatory cytokines released from 
immune cells at the site of inflammation [15,34], albeit the polarization toward anti-inflammatory 
phenotype may depend on the concentration and duration of the stimulating agent or the type of 
the factor itself [33]. The site of inflammation abounds in pro-inflammatory mediators, including 
IFN-γ and TNF-α [35]. For priming of MSC’s immunosuppressive function, the combination of 
IFN-γ and TNF-α or IL-1α/β was recommended [15]. The production of numerous cytokines and 
chemokines involved in MSCs’ T-cell inhibitory machinery in mouse or in human (IL-6, IL-8, 
IL-10, HGF, PD-L1, PGE2, NO and IDO1) are induced by priming MSCs with IFN-γ and TNF-α 
[15,31,36,37]. In the present study, the combination of IFN-γ and TNF-α was applied for the 
priming of MSC inhibitory activity to model an inflammatory milieu. The pre-treatment of MSC 
clones with IFN-γ and TNF-α equated the inhibition of T-cell proliferation hence clones, MSC3 
and MSC6, inhibiting poorly the T-cell proliferation, acquired similarly strong inhibitory 
activities to those of MSC2, MSC4 and MSC5. This result indicated that stimulation of MSC 
clones with IFN-γ and TNF-α enhanced the immunosuppressive effect of otherwise non-
functional single cell-derived MSC cultures. Indeed, licensing MSC clones resulted in a 
remarkable upregulation of Nos2 and Ido1 and various moderate increase of Ptgs2 gene 
expression in every MSC clone. Examining the role of inflammatory cytokines we found that the 
NOS2 expression was essential since its inhibitor L-NMMA reversed T-cell proliferation in 
licensed MSC2 and MSC6 clones. Inhibition of PGE2 synthase reversed only partially the 
suppression by MSC6 but did not affect that by MSC2. These results might allow the conclusion 
that MSC population has an intrinsic heterogeneity regarding the mediators of the 
immunosuppressive function, such as PTGS2.  
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Induction of Ido1 mRNA expression under inflammatory conditions was the most striking since 
naïve clones did not express the gene at all whereas remarkable increase occurred upon IFN-γ 
and TNF-α treatment. In spite of the high gene expression of Ido1, IDO1 inhibitor, 1-MT did not 
affect activities of licensed MSC clones. Although IDO1 is an important factor in human MSC 
[38], its function in mouse MSCs is inconsistent. Even though Ido1 mRNA expression is 
inducible with pro-inflammatory cytokines, the IDO1 protein expression is undetectable in mouse 
MSC [39]. One possible explanation was served by Hucke et al. showing that an accelerated 
proteosomal degradation of IDO protein occurred upon NO production [40]. Accordingly, 
chemical inhibition of IDO1 in mouse MSCs did not affect MSC function on T-cell proliferation. 
[15,30,38].  
Experimental animal models clearly revealed that MSCs could be effective cell-based 
therapies in immunological pathologies [17,18,41-43]. Whether in vivo immunoregulatory 
property of MSCs was reflected at clonal level the effects of the most and least 
immunosuppressive clones, MSC2 and MSC6, respectively, were examined in ovalbumin-
induced delayed-type hypersensitivity (DTH) model. The in vitro results were validated in vivo, 
since MSC2 diminished whereas MSC6 did not affect DTH response when naïve MSC clones 
were applied. In contrast, pre-treatment of MSC6 with licensing cytokines IFN-γ and TNF-α 
prior to intraperitoneal injection resulted in similar blocking effect of MSC6 to that of MSC2 
indicating the increasing immunosuppressive function of an otherwise poorly acting clone. Our 
results were supported by the data obtained in GVHD model since pre-activation of MSCs 
resulted in more effective prevention of the disease [17].  
Taken together, our experiments clearly show that murine MSC population possesses 
intrinsic heterogeneity regarding the immunosuppressive function of single cell-derived MSC 
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clones. Variations between the clones can be at least partly, explained by the different expression 
of immunoregulatory factors. In this sense, NO is the key mediator while PGE2 is involved and 
IDO1 has no role in the suppressive activity of MSC clones. An important novel message of this 
work is that variability in the immune function of the different MSC clones can be abolished by 
licensing the cells by inflammatory cytokines prior to application for immunological assays or 
therapy of immune disorders. 
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Figure legend 
FIG. 1. Expression of cell surface markers of monoclonal MSC lines. MSC clones 2-6 
were labeled with antibodies to CD11b, CD45, Sca-1, CD29, CD44, CD106 or 
CD119 (black lines). The negative controls were isotype matching immunoglobulins 
(grey shadowed area). Samples were then analyzed with flow cytometry.  
 
FIG. 2. In vitro adipogenic and osteogenic differentiation of MSC clones. Cells were 
induced to differentiate toward osteoblastic (A) and adipocytic (B) lineage. In 
osteogenic cultures calcium accumulations were stained with Alisarin Red S on the 
14
th
 day (A). Adipogenic cultures were fixed and stained with AdipoRed™ on the 3
rd
 
day (B) and lipid accumulation was quantified by flow cytometry (C). The pictures 
are representatives of 3 independe t experiments. Scale bar = 50 µm (A and B) 
 
FIG. 3. Monoclonal MSC lines exhibit similar pro-angiogenic activity. MSCs were 
co-cultured with or without H5V in 1 : 1 ratio for 3 days. Pre-vascular structures were 
visualized with Olympus Cell-R fluorescence microscope using UPlanSApo 4x/0.16 
objective (representative images selected from three independent experiments) (A). 
Lengths of the structures were measured in 5 randomly selected non-overlapping 
areas of co-plated cells using CellR Imaging Software. Averages and deviations were 
calculated using data of three independent experiments (B). Expressions of pro-
angiogenic factors, Angpt1, Vegfa and Lgals1, were determined from total mRNA 
extract prepared from MSC2-6 with qPCR. Gapdh expression served as internal 
control. Results of three independent experiments were used to draw the graphs (C).  
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FIG. 4. MSC cell lines vary in immunosuppressive activity. Cytofluorimetric profiles 
of CFSE labeled T-cells under different conditions are presented (representative 
experiment) (A).Freshly isolated, CFSE-labeled lymph node cells were co-cultured 
with or without MSC clones at 40 to 1 ratio in the presence of Con A. The day before 
co-culture with T-cells MSC were plated without (B) or with 100 ng/mL IFN-γ and 
50 ng/mL TNF-α for 24 hours (C). T-cell proliferation was evaluated after 72 hours 
by flow cytometry and data were analyzed by ModFit LT
TM
 software. The data shown 
on (B) and (C) are the means of 5 independent experiments. Each experiment was 
carried out in triplicates (n = 15). n.s. = not significant, p > 0.05, * p < 0.05; ** 
p < 0.01; *** p < 0.001. 
 
FIG. 5. Expression levels of genes affecting immunosuppressive function of MSCs. 
Total RNA was extracted from cells cultured for 24 h in the absence or presence of 
100 ng/mL IFN-γ and 50 ng/mL TNF-α and expression levels of Nos2 (A), Ptgs2 (B) 
were analyzed by qPCR. Gapdh served as a housekeeping gene. The results are the 
averages of 2 independent experiments +S.E.M.  
 
FIG. 6. The role of NO and PGE2 in the inhibition of T-cell proliferation by MSC2 
and MSC6. MSCs were plated on 96-well plates, left unstimulated or pre-activated 
with 100 ng/mL IFN-γ and 50 ng/mL TNF-α for 24 hours. After 24 hours, MSCs were 
washed with DMEM, co-cultured with freshly isolated, CFSE-labeled lymph node 
cells in 1 to 40 ratio with or without 1mM L-NMMA or 10 μM indomethacin (Indo). 
Proliferation of T-cells was stimulated by Con A. After 72 hours of co-culture of 
MSCs and T-cells, proliferation of T-cells was assessed by cytofluorometry and data 
were analyzed by ModFit LT
TM 
software. The figure shows the percent of 
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proliferating T-cells.. Con A-activated T-cells cultured with or without L-NMMA or 
indomethacin in the absence of MSCs served as positive controls. The data are the 
representative of three independent experiments + SD. The experiments were 
performed in triplicate. n.s. = not significant p > 0.05; *p < 0.05; **p < 0.01; 
***p < 0.001. 
 
FIG. 7. Effect of intraperitoneal injection of MSC2 and MSC6 in ovalbumin-induced 
delayed type hypersensitivity (DTH) model. Hypersensitivity was triggered in male 
C57BL/6 mice with subcutaneous administration of ovalbumin. At the same time, 
mice were injected intraperitoneally with 10
6 
MSC2 or 10
6
 MSC6 untreated or 
pretreated with IFN-γ and TNF-α in PBS or with PBS alone. After 4 days, heat 
aggregated ovalbumin was injected into the right and PBS in the left hind footpad. 
After 48 hours, ovalbumin-induced footpad thickness increment was measured. RFI, 
relative footpad increment, was calculated as follows: RFI = (treated48 h -
 untreated48 h)-(treated0 h - untreated0 h). The data are the means of two independent 
experiments. One-way ANOVA, Fisher’s LSD multiple comparison test was used for 
statistical analysis, n.s. p > 0.05, *p < 0.05; **p < 0.01. Black lines mark the average 
footpad thickness increment in each experimental group. 
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Supplementary Data 
 
SUPPLEMENTARY FIG. S1. MSC clones express similar amount of galectin-1 (Gal-
1). 
 
MSCs were lysed in RIPA buffer, and 30 µg protein of the lysates/sample were 
analyzed by Western blot after running the samples on a 10% SDS-polyacrylamide 
gel. Polyclonal rabbit anti-Gal-1 and HRP-conjugated anti-rabbit immunoglobulins 
were applied for Gal-1 detection. Rabbit anti-β-actin was used as loading control. 
Density of the bands was determined by VisionWorks
®
LS Image Acquisition and 
Analysis Software (Ultra-Violet Products). 
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SUPPLEMENTARY FIG. S2. Tgfb1 mRNA expression levels of MSC clones under 
normal culture conditions. After 2 days of culture, total RNA was isolated from cells 
and analyzed by qPCR. Data were normalized to the expression level of housekeeping 
gene Gapdh. 
 
 
SUPPLEMENTARY FIG. S3. The expression and role of IDO1 in the inhibition of 
unstimulated and pre-activated MSC2 and MSC6. (A) MSCs were treated with 
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100 ng/mL IFN-γ and 50 ng/mL TNF-α for 24 hours or left unstimulated. After 24 
hours cytokine treatment total RNA was isolated and Ido1 gene expression analyzed 
by qPCR. Gapdh expression served as an internal control. (B) MSCs were plated on a 
96-well culture plate, pre-treated with 100 ng/mL IFN-γ plus 50 ng/mL TNF-α for 24 
hours or left unstimulated. After 24 hours, MSCs were washed with medium, co-
cultured with freshly isolated, CFSE-labeled lymph node cells in 1 to 40 ratio with or 
without 1 mM 1-MT. T-cells were activated with Con A. After 72 hours of co-culture, 
proliferation of T-cells was assessed by flow cytometry and data were analyzed by 
ModFit LT
TM 
Version 2.0. software. The figure shows the percent of proliferating T-
cells. Con A-activated T-cells alone with or without 1 mM 1-MT served as positive 
controls. The data are the representative experiment + SD, which was carried out in 
triplicate. n.s. = not significant p > 0.05 
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